Abstract:Prion diseases are fatal neurodegenerative disorders where the formation of amyloids is thought to be infectious by templating their conformation on to natively-folded counterparts. Postulated nearly four decades ago, the search for the mechanism behind the conformational templating has proceeded to no avail. Here, we extend the thermodynamic hypothesis of protein folding (Anfinsen's dogma) to the amyloid phenomenon and illustrate that the amyloid conformation (cross-β) is one of two conformational states that are thermodynamically accessible to any protein sequence depending on concentration. A protein spontaneously assumes its native conformation below supersaturation and the amyloid cross-β conformation above supersaturation. The information to adopt the native conformation and the amyloid conformation is present in the primary sequence and the backbone of the protein, respectively, and does not require templating. The rate-limiting step for proteins to adopt the cross-β conformation of amyloid is termed nucleation, which can be catalyzed by surfaces (heterogeneous nucleation) or preformed amyloid fragments (seeding). Irrespective of the nucleation pathway, once triggered, amyloid formation proceeds spontaneously in fractal-like fashion, where the surfaces of the growing fibrils act as heterogeneous nucleation catalysts for new fibrils, a phenomenon known as secondary nucleation. This pattern is in contrast to the linear growth assumptions that the prion hypothesis necessitates for faithful prion strain replication. Additionally, the cross-β conformation buries the majority of the protein side chain inside the fibrils, making the fibrils inert, generic, and extremely stable. As such, the source of toxicity in prion disorders may come to a greater extent from the loss of proteins in their normal, soluble, and therefore functional state rather than from their transformation into stable, insoluble, nonfunctioning amyloids.

Pathways of amyloid fibril formation and protein aggregation

Factors influencing amyloid fibril formation

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Amyloid-Induced Neurodegeneration: A Comprehensive Review through Aggregomics Perception of Proteins in Health and Pathology

Mechanisms and pathology of protein misfolding and aggregation

Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation

Experimental techniques for detecting and evaluating the amyloid fibrils

Protein aggregation: An overview

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Protein aggregation and its affecting mechanisms in neurodegenerative diseases

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Amyloid fibril cytotoxicity and associated disorders

The allure and pitfalls of the prion-like aggregation in neurodegeneration

Protein aggregation, misfolding and consequential human neurodegenerative diseases

Realization of Amyloid-like Aggregation as a Common Cause for Pathogenesis in Diseases

Aggregation mechanisms and molecular structures of amyloid‐β in Alzheimer's disease

Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases

The role of α-sheet structure in amyloidogenesis: characterization and implications

Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases